Carcinoma ex Pleomorphic Adenoma: A Comprehensive Review of Clinical, Pathological and Molecular Data
Tóm tắt
Từ khóa
Tài liệu tham khảo
Gnepp DR. Malignant mixed tumours of the salivary glands: a review. Pathol Annu. 1993;28:279–328.
Nouraei SA, Hope KL, Kelly CG, et al. Carcinoma ex benign pleomorphic adenoma of the parotid gland. Plast Reconstr Surg. 2005;116:1206–13.
Kuroishikawa M, Kiyosawa M, Akashi T, et al. Case of lacrimal gland carcinoma ex adenoma. Jpn J Ophthalmol. 2004;48:181–2.
Malata CM, Camilleri IG, McLean NR, et al. Malignant tumours of the parotid gland: a 12 year review. Br J Plast Surg. 1997;50:600–8.
Byrne MN, Spector JG. Parotid masses: evaluation, analysis, and current management. Laryngoscope. 1988;98:99–105.
Zbären P, Zbären S, Caversaccio MD, Stauffer E. Carcinoma ex pleomorphic adenoma: diagnostic difficulty and outcome. Otolaryngol Head Neck Surg. 2008;138:601–5.
Olsen KD, Lewis JE. Carcinoma ex pleomorphic adenoma: a clinicopathological review. Head Neck. 2001;23:705–12.
Damm DD, Fantasia JE. Large palatal mass. Carcinoma ex-pleomorphic adenoma. Gen Dent. 2001;49:574–658.
Yoshihara T, Tanaka M, Itoh M, et al. Carcinoma ex pleomorphic adenoma of the soft palate. J Laryngol Otol. 1995;109:240–3.
Hayes MM, Lesack D, Girardet C, et al. Carcinoma ex-pleomorphic adenoma of the breast. Report of three cases suggesting a relationship to metaplastic carcinoma of matrix-producing type. Virchows Arch. 2005;446:142–9.
Baredes S, Ludwin DB, Troublefield YL, et al. Adenocarcinoma ex-pleomorphic adenoma of the lacrimal sac and nasolacrimal duct: a case report. Laryngoscope. 2003;113:940–2.
Ding CS, Yap WM, Teo CH, et al. Tracheal carcinoma ex pleomorphic adenoma: a rare tumour with potential problems in diagnosis. Histopathology. 2007;51:868–71.
Cho KJ, el-Naggar AK, Mahanupab P, et al. Carcnioma ex-pleomorphic adenoma of the nasal cavity: a report of two cases. J Laryngol Otol. 1995;109:677–9.
Park KC, Choi HJ, Kwon JK. Carcinoma ex pleomorphic adenoma mimicking multiple facial nerve schwannoma. Auris Nasus Larynx. 2008;35:291–4.
Dewan K, Owens J, Silvester K. Maintaining a high level of suspicion for recurrent malignant disease: report of a case with periapical involvement. Int Endod J. 2007;40:900–7.
Luers JC, Wittekindt C, Streppel M, et al. Carcinoma ex pleomorphic adenoma of the parotid gland. Study and implications for diagnostics and therapy. Acta Oncol. 2009;48:132–6.
Lewis JE, Olsen KD, Sebo TJ. Carcinoma ex pleomorphic adenoma: pathological analysis of 73 cases. Hum Pathol. 2001;32:596–604.
Barnes L, Eveson JW, Reichart P, Sidransky D, editors. World health organisation classification of tumours. Pathology and genetics of head and neck tumours. Lyon: IARC Press; 2005.
Altemani A, Martins MT, Freitas L, et al. Carcinoma ex pleomorphic adenoma (CXPA): immunoprofile of the cells involved in carcinomatous progression. Histopathology. 2005;46:635–41.
LiVolsi VA, Perzin KH. Malignant mixed tumours: a clinicopathological study. Cancer. 1977;39:2209–30.
Demasi AP, Furuse C, Soares AB, et al. Peroxiredoxin I, platelet-derived growth factor A, and platelet-derived growth factor receptor alpha are overexpressed in carcinoma ex pleomorphic adenoma: association with malignant transformation. Human Pathol. 2009;40:390–7.
Di Palma S, Skalova A, Vanieek T, et al. Non-invasive (intracapsular) carcinoma ex pleomorphic adenoma: recognition of focal carcinoma by HER-2/neu and MIB1 immunohistochemistry. Histopathology. 2005;46:144–52.
Brandwein M, Huvos AG, Dardick I, et al. Noninvasive and minimally invasive carcinoma ex mixed tumor. A clinicopathologic and ploidy study of 12 patients with major salivary tumors of low (or no) malignant potential. Oral Surg Oral Med Oral Pathol Radiol Endod. 1996;81:655–64.
Negahban S, Daneshbod Y, Shishegar M. Clear cell carcinoma arising from pleomorphic adenoma of a minor salivary gland: report of a case with fine needle aspiration, histologic and immunohistochemical findings. Acta Cytol. 2006;50:687–90.
Nakamori K, Ohuchi T, Hasegawa T, et al. Carcinoma ex pleomorphic adenoma of the buccal region is composed of salivary duct carcinoma and squamous cell carcinoma components. Int J Oral Maxillofac Surg. 2009;38:1116–8.
Kato H, Kanematsu M, Mizuta K, et al. Carcinoma ex pleomorphic adenoma of the parotid gland: radiologic-pathologic correlation with MR imaging including diffusion-weighted imaging. Am J Neuroradiol. 2008;29:865–7.
Klijanienko J, El-Naggar AK, Vielh P. Fine-needle sampling findings in 26 carcinoma ex pleomorphic adenomas: diagnostic pitfalls and clinical considerations. Diagn Cytopathol. 1999;21:163–6.
Raine C, Saliba K, Chippindale AJ, et al. Radiological imaging in primary parotid malignancy. Br J Plast Surg. 2003;56:637–43.
Di Palma S, Lambros MB, Savage K, et al. Oncocytic change in pleomorphic adenoma: molecular evidence in support of an origin in neoplastic cells. J Clin Pathol. 2007;60:492–9.
Rodriguez-Fernandez J, Mateos-Micas M, Martinez-Tello FJ, et al. Metastatic benign pleomorphic adenoma: report of a case and review of the literature. Med Oral Patol Oral Cir Bucal. 2008;13:193–6.
El-Naggar AK, Callender D, Coombes MM, et al. Molecular genetic alterations in carcinoma ex-pleomorphic adenoma: a putative progression model? Genes Chromosomes Cancer. 2000;27:162–8.
Röijer E, Nordkvist A, Ström AK, et al. Translocation, deletion/amplification, and expression of HMGIC and MDM2 in a carcinoma ex pleomorphic adenoma. Am J Pathol. 2002;160:433–40.
Martins C, Fonseca I, Roque L, et al. PLAG1 gene alterations in salivary gland pleomorphic adenoma and carcinoma ex-pleomorphic adenoma: a combined study using chromosome banding, in situ hybridization and immunocytochemistry. Mod Pathol. 2005;18:1048–55.
Fowler MH, Fowler J, Ducatman B, et al. Malignant mixed tumors of the salivary gland: a study of loss of heterozygosity in tumor suppressor genes. Mod Pathol. 2006;19:350–5.
Righi PD, Li YQ, Deutsch M, McDonald JS, et al. The role of the p53 gene in the malignant transformation of pleomorphic adenomas of the parotid gland. Anticancer Res. 1994;14:2253–7.
Ihrler S, Weiler C, Hirschmann A, Sendelhofert A, et al. Intraductal carcinoma is the precursor of carcinoma ex pleomorphic adenoma and is often associated with dysfunctional p53. Histopathology. 2007;51:362–71.
Nordkvist A, Röijer E, Bang G, Gustafsson H, et al. Expression and mutation patterns of p53 in benign and malignant salivary gland tumors. Int J Oncol. 2000;16:477–83.
Gedlicka C, Item CB, Wögerbauer M, et al. Transformation of pleomorphic adenoma to carcinoma ex pleomorphic adenoma of the parotid gland is independent of p53 mutations. J Surg Oncol. 2010;101:127–30.
Patel RS, Rose B, Bawdon H, Hong A, et al. Cyclin D1 and p16 expression in pleomorphic adenoma and carcinoma ex pleomorphic adenoma of the parotid gland. Histopathology. 2007;51:691–6.
Tarakji B, Nassani MZ, Sloan P. Immunohistochemical expression of estrogens and progesterone receptors in carcinoma ex pleomorphic adenoma-undifferentiated and adenocarcinoma types. Med Oral Patol Oral Cir Bucal. 2010;15:432–6.
Katori H, Nozawa A, Tsukuda M. Expression of epidermal growth factor receptor, transforming growth factor-alpha and Ki-67 in relationship to malignant transformation of pleomorphic adenoma. Acta Otolaryngol. 2007;127:1207–13.
Kawata R, Hyo S, Araki M, et al. Expression of cyclooxygenase-2 and microsomal prostaglandin E synthase-1 in head and neck squamous cell carcinoma. Auris Nasus Larynx. 2010;37:482–7.
Katori H, Nozawa A, Tsukuda M. Increased expression of cyclooxygenase-2 and Ki-67 are associated with malignant transformation of pleomorphic adenoma. Auris Nasus Larynx. 2007;34:79–84.
Powers CJ, McLeskey SW, Wellstein A. Fibroblast growth factors, their receptors and signaling. Endocr Relat Cancer. 2000;7:165–97.
Martinez EF, Demasi AP, Miguita L, et al. FGF-2 is overexpressed in myoepithelial cells of carcinoma ex-pleomorphic adenoma in situ structures. Oncol Rep. 2010;24:155–60.
Furuse C, Miguita L, Rosa AC, et al. Study of growth factors and receptors in carcinoma ex pleomorphic adenoma. J Oral Pathol Med. 2010;39:540–7.
Sugawara K, Mori S, Morita M. Expression of c-erbB-2 protein detected in adenocarcinoma arising from parotid pleomorphic adenoma. Auris Nasus Larynx. 1990;17:115–20.
Müller S, Vigneswaran N, Gansler T, et al. c-erbB-2 oncoprotein expression and amplification in pleomorphic adenoma and carcinoma ex pleomorphic adenoma: relationship to prognosis. Mod Pathol. 1994;7:628–32.
Rosa JC, Fonseca I, Félix A, et al. Immunohistochemical study of c-erbB-2 expression in carcinoma ex-pleomorphic adenoma. Histopathology. 1996;28:247–52.
Sharon E, Kelly RJ, Szabo E. Sustained response of carcinoma ex pleomorphic adenoma treated with trastuzumab and capecitabine. Head Neck Oncol. 2010;2:12.
Prabhu S, Kaveri H, Rekha K. Benign and malignant salivary gland tumors: comparison of immunohistochemical expression of e-cadherin. Oral Oncol. 2009;45:594–9.
Economopoulou P, Hanby A, Odell EW. Expression of E-cadherin, cellular differentiation and polarity in epithelial salivary neoplasms. Oral Oncol. 2000;36:515–8.
Saleh ER, França CM, Marques MM. Neural adhesion molecule (N-CAM) in pleomorphic adenoma and carcinoma ex-pleomorphic adenoma. J Oral Pathol Med. 2003;32:562–7.
Genelhu MC, Gobbi H, Arantes DC, et al. Immunolocalization of beta-catenin in pleomorphic adenomas and carcinomas ex-pleomorphic adenomas of salivary glands. Appl Immunohistochem Mol Morphol. 2007;15:273–8.